Following a rigorous selection process, Moorfields Eye Hospital optometrist, Josie Carmichael, will start a year-long NHS Fellowship in Clinical AI on 13 August. Healthcare professionals from a ...

Key Points Non-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. GAAP revenue reached $687.5 million for Q2 2025, beating expectations by $33.6 million and ...

Q2 2025 Management View CEO Robert Barrow highlighted that MindMed remains "on track with enrollment with our three pivotal Phase III trials for our lead asset, MM120 ODT, which is being evaluated in ...

The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, ...

The key news from the release was that while the company outperformed revenue estimates—reporting $28.2 million (GAAP) compared to the expected $27.03 million—profitability came under pressure, with a ...

A study published in the International Journal of Radiation Oncology*Biology*Physics demonstrates that clinicopathology (CP) ...

Sava Technologies announced today that it raised $19 million in a Series A financing round to support its wearable biosensor ...

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., Jul ...

Q2 2025 Management View Kabir Kumar Nath, CEO, announced the appointment of Justin Gover, former CEO of GW Pharmaceuticals, ...

With Human Research Ethics Committee (HREC) approval already secured, Oragenics is working closely with Southern Star to complete site selection, finalize investigator agreements, and prepare for ...